<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00138216</url>
  </required_header>
  <id_info>
    <org_study_id>ADVL0414</org_study_id>
    <secondary_id>COG-ADVL0414</secondary_id>
    <secondary_id>CDR0000440069</secondary_id>
    <nct_id>NCT00138216</nct_id>
  </id_info>
  <brief_title>Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors</brief_title>
  <official_title>A Phase I Study of Temozolomide, Oral Irinotecan, and Vincristine for Children With Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as temozolomide, vincristine, and irinotecan,&#xD;
      work in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill&#xD;
      more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of irinotecan when&#xD;
      given together with temozolomide and vincristine in treating young patients with refractory&#xD;
      solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose and recommended phase II dose of irinotecan when&#xD;
           administered with temozolomide and vincristine in young patients with refractory solid&#xD;
           tumors, including brain tumors.&#xD;
&#xD;
        -  Determine the toxic effects of this regimen in these patients.&#xD;
&#xD;
        -  Compare the toxic effects of this regimen in patients with low- vs high-risk UGT1A1&#xD;
           genotypes.&#xD;
&#xD;
        -  Determine the pharmacokinetics of irinotecan in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine, preliminarily, the antitumor activity of this regimen in these patients.&#xD;
&#xD;
        -  Correlate UGT1A1, UGT1A7, UGT1A9, and BCRP genotypes with the pharmacokinetics and&#xD;
           pharmacodynamics of irinotecan and its metabolites in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of irinotecan. Patients are stratified&#xD;
      according to UGT1A1 genotype (high-risk [7/7 or 6/7 genotype AND bilirubin ≥ 0.6 mg/dL] vs&#xD;
      low-risk [absence of high-risk criteria]) if a high-risk patient experiences a dose-limiting&#xD;
      toxicity (DLT).&#xD;
&#xD;
      Patients receive oral temozolomide on days 1-5 and oral irinotecan on days 1-5 and 8-12.&#xD;
      Patients also receive vincristine IV over 1 minute on days 1 and 8. Treatment repeats every&#xD;
      21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of irinotecan until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6&#xD;
      patients experience DLT.&#xD;
&#xD;
      After completion of study treatment, patients are followed for 1 month and then annually&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-36 patients will be accrued for this study within 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine maximum tolerated dose (MTD) of oral irinotecan</measure>
    <time_frame>length of study</time_frame>
    <description>To estimate the maximum tolerated dose (MTD) of oral irinotecan administered on two different schedules together with fixed-dose temozolomide and vincristine in children with refractory solid tumors or brain tumors</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To preliminarily define the antitumor activity</measure>
    <time_frame>Length of study</time_frame>
    <description>To preliminarily define the antitumor activity of this drug combination within the confines of a Phase 1 study.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Oral Irinotecan, temozolomide and vincristine sulfate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>see detailed description</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <arm_group_label>Oral Irinotecan, temozolomide and vincristine sulfate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
    <arm_group_label>Oral Irinotecan, temozolomide and vincristine sulfate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <arm_group_label>Oral Irinotecan, temozolomide and vincristine sulfate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed* malignant solid tumor, including brain tumor, at original&#xD;
             diagnosis or relapse&#xD;
&#xD;
               -  Refractory disease NOTE: *Histologic confirmation not required for intrinsic&#xD;
                  brain stem tumors&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  No known curative therapy OR therapy proven to prolong survival with an acceptable&#xD;
             quality of life exists&#xD;
&#xD;
          -  No known bone marrow metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  1 to 21&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Lansky 50-100% (for patients ≤ 10 years of age)&#xD;
&#xD;
          -  Karnofsky 50-100% (for patients &gt; 10 years of age)&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3 (transfusion independent)&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL (RBC transfusions allowed)&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  ALT ≤ 110 U/L (upper limit of normal [ULN] for ALT is 45 U/L)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  Albumin ≥ 2 g/dL&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min OR&#xD;
&#xD;
          -  Creatinine based on age as follows:&#xD;
&#xD;
               -  No greater than 0.8 mg/dL (for patients ≤ 5 years of age)&#xD;
&#xD;
               -  No greater than 1.0 mg/dL (for patients 6 to 10 years of age)&#xD;
&#xD;
               -  No greater than 1.2 mg/dL (for patients 11 to 15 years of age)&#xD;
&#xD;
               -  No greater than 1.5 mg/dL (for patients &gt; 15 years of age)&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Neurologic deficits in patients with CNS tumors must be stable for ≥ 1 week prior to&#xD;
             study entry&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No documented allergy to cephalosporins or dacarbazine&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Recovered from prior immunotherapy&#xD;
&#xD;
          -  At least 3 months since prior stem cell transplantation or rescue without total-body&#xD;
             irradiation&#xD;
&#xD;
               -  No evidence of active graft-versus-host disease&#xD;
&#xD;
          -  At least 7 days since prior antineoplastic biologic agents&#xD;
&#xD;
          -  At least 7 days since prior hematopoietic growth factors&#xD;
&#xD;
          -  No concurrent biologic therapy or immunotherapy&#xD;
&#xD;
          -  No concurrent prophylactic filgrastim (G-CSF) during the first course of study&#xD;
             treatment&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Recovered from prior chemotherapy&#xD;
&#xD;
          -  Prior temozolomide, vincristine, irinotecan, or topotecan allowed&#xD;
&#xD;
               -  No prior coadministration of temozolomide and irinotecan&#xD;
&#xD;
               -  No disease progression during treatment with either irinotecan or temozolomide&#xD;
&#xD;
          -  More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas)&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Patients with CNS tumors must be on a stable or decreasing dose of dexamethasone for ≥&#xD;
             7 days prior to study entry&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
          -  At least 6 months since prior total-body irradiation, craniospinal radiotherapy, or&#xD;
             radiotherapy to ≥ 50% of the pelvis&#xD;
&#xD;
          -  At least 6 weeks since other prior substantial bone marrow radiotherapy&#xD;
&#xD;
          -  At least 2 weeks since prior local palliative radiotherapy (small port)&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No concurrent enzyme-inducing anticonvulsants, including any of the following:&#xD;
&#xD;
               -  Phenobarbital&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Oxcarbazepine&#xD;
&#xD;
          -  No concurrent administration of any of the following:&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Voriconazole&#xD;
&#xD;
               -  Itraconazole&#xD;
&#xD;
               -  Ketoconazole&#xD;
&#xD;
               -  Aprepitant&#xD;
&#xD;
               -  Hypericum perforatum (St. John's wort)&#xD;
&#xD;
          -  No concurrent treatment for clostridium difficile infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars M. Wagner, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John P. Perentesis, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital - Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5289</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Masonic Cancer Center at University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University Hospital</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital - Muhlenberg</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-9786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Regional Medical Center - Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Sainte Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Wagner LM, Perentesis JP, Reid JM, Ames MM, Safgren SL, Nelson MD Jr, Ingle AM, Blaney SM, Adamson PC. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study. Pediatr Blood Cancer. 2010 Apr;54(4):538-45. doi: 10.1002/pbc.22407.</citation>
    <PMID>20049936</PMID>
  </results_reference>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>August 29, 2005</study_first_submitted>
  <study_first_submitted_qc>August 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2005</study_first_posted>
  <last_update_submitted>February 18, 2014</last_update_submitted>
  <last_update_submitted_qc>February 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <keyword>recurrent childhood cerebellar astrocytoma</keyword>
  <keyword>recurrent childhood cerebral astrocytoma</keyword>
  <keyword>recurrent childhood brain stem glioma</keyword>
  <keyword>recurrent childhood brain tumor</keyword>
  <keyword>recurrent childhood ependymoma</keyword>
  <keyword>recurrent childhood medulloblastoma</keyword>
  <keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>recurrent childhood visual pathway and hypothalamic glioma</keyword>
  <keyword>childhood oligodendroglioma</keyword>
  <keyword>childhood craniopharyngioma</keyword>
  <keyword>childhood choroid plexus tumor</keyword>
  <keyword>childhood infratentorial ependymoma</keyword>
  <keyword>childhood supratentorial ependymoma</keyword>
  <keyword>childhood high-grade cerebral astrocytoma</keyword>
  <keyword>childhood low-grade cerebral astrocytoma</keyword>
  <keyword>childhood central nervous system germ cell tumor</keyword>
  <keyword>childhood grade I meningioma</keyword>
  <keyword>childhood grade II meningioma</keyword>
  <keyword>childhood grade III meningioma</keyword>
  <keyword>recurrent childhood subependymal giant cell astrocytoma</keyword>
  <keyword>childhood atypical teratoid/rhabdoid tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

